EGFR and breast cancer: Specifically, pachycladin A (compound 1) reduced the growth of MDA-MB-231 breast cancer cells (EC50 of 1.6 μM) [49]; this was accompanied by the inhibition of EGFR kinase activity (10 μM) as well as p-EGFR protein levels (0.5–4 μM) [49].